Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs

Current Drug Metabolism

Volumn 13, Issue 6, 2012, Pages 835-862

  Hartyanszky I ^a   Kalasz H ^a,b   Adeghate, E ^b   Gulyas Zs ^c   Hasan, M Y ^b   Tekes, K ^a   Adem, A ^b   Sotonyi P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c Thalesnano Inc   (Hungary)

Author keywords

Active metabolites; Metabolic decarboxylation; Metabolic reduction and metabolic hydrolysis

Indexed keywords

ACETOHEXAMIDE; ACETYLSALICYLIC ACID; BACAMPICILLIN; BAMBUTEROL; BENAZEPRIL; CANDESARTAN HEXETIL; CAPTOPRIL; CEFOTAXIME; CEFPODOXIME PROXETIL; CLORAZEPATE; DOPAMINE; DOXORUBICIN; EPIRUBICIN; ESTER; HALOPERIDOL; HYDROXYHEXAMIDE; IDARUBICIN; LEVODOPA; LOPERAMIDE 1 OXIDE; MITOMYCIN C; NORDAZEPAM; OMEPRAZOLE; OXAZEPAM; OXCARBAZEPINE; PALIPERIDONE; PREDNISONE; RISPERIDONE; SALAZOSULFAPYRIDINE; SULFAMIDOCHRYSOIDINE;

ANXIETY DISORDER; ASTHMA; BLADDER CANCER; BLOOD BRAIN BARRIER; BREAST CANCER; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DECARBOXYLATION; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENTERITIS; FOCAL EPILEPSY; GASTROESOPHAGEAL REFLUX; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; HYDROPHILICITY; HYPERTENSION; INFLAMMATION; IRRITABLE COLON; LEUKEMIA; LIP CANCER; LIPOPHILICITY; LOWER RESPIRATORY TRACT INFECTION; LYMPHOMA; METABOLITE; MOUTH CANCER; NONHUMAN; PARKINSON DISEASE; PERITONEUM CANCER; PHARYNX CANCER; REDUCTION; REVIEW; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER RESPIRATORY TRACT INFECTION;

BIOTRANSFORMATION; DECARBOXYLATION; ESTERS; HUMANS; HYDROLYSIS; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS;

EID: 84863655870     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800840437     Document Type: Review

References (173)

1. Pliska, V.; Testa, B.; van de Waternbeemd, H. 1. Lipophilicity: The empirical tool and the fundamental objective. An introduction. In: Lipophilicity in Drug Action and Toxicology, Pliska, V.; Testa, B.; van de Waternbeemd (Eds.), VCH, Weinheim, 1996, pp. 1-6.
2. Sandberg, M.; Eriksson, L.; Jonsson, J.; Sjöström, M.; Wold, S. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J. Med. Chem., 1998, 41, 2481-2491.
3. Available from: www.drugbank.ca
4. Available from: http://www.syrres.com/what-we-do/databaseforms.aspx
5. logP and TPSA were calculated by Prolog P, Pallas 3.7 program, The Pallas PrologP program is a Trademark of CompuDrug, Inc., www.compudrug.com.
6. Frey, H.H.; Scherkl, R. Clorazepate, correlation between metabo-lism and anticonvulsant activity. Eur. J. Pharmacol. 1988, 158, 213-216.
7. http://www.merck.com/mmpe/print/lexicomp/clorazepate.html
8. Pávek, P.; Staud, F.; Fendrich, Z.; Maláková, J.; Palicka, V., Transfer of clorazepate and nordiazepam across the umbilically perfused rat term placenta in situ: Comparison with flunitrazepam and diazepam. Placenta, 1999, 20, Suppl. 1, 329-342.
9. Rang, H.P.; Dale, M.M.; Ritter, J.M.; Flower, R.J., Eds. Rang and Dale's Pharmacology, 6th ed; Churchill Livingstone Elsevier: Amsterdam, 2007, pp. 519-520.
10. Lloyd, K.; Hornykiewicz, O. Parkinson's Disease: Activity of L-Dopa decarboxylase in discrete brain regions Science, 1970, 170, 1212-1213.
11. Rahman, M.K.; Toshiharu, N.; Takeshi, K. Aromatic l-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with l-dopa and l-5-hydroxytryptophan as substrates. Biochem. Pharmacol. 1981, 30, 645-649.
12. Shahabi, H.N.; Bergquist, F.; Nissbrandt, H. An investigation of dopaminergic metabolites in the striatum and in the substantia nigra in vivo utilizing radiolabelled L-DOPA and high performance liquid chromatography: a new approach in the search for transmitter metabolites. Neurosci., 2003, 120, 425-433.
13. Ferner, R.E.; Chaplin, S. The relationship between the pharma-cokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin. Pharmacokinet. 1987, 12, 379-401.
14. Ku, Y.R.; Chag, L.Y.; Ho, L.K.; Lin, J.H. Analysis of synthetic anti-diabetic drugs in adulterated traditional Chinese medicines by high-performance capillary electrophoresis. J. Pharm. Biomed. Anal., 2003, 33, 329-334.
15. http://www.accessmedicine.com/popup.aspx?aID=959800
16. Minotti, G.; Ronchi, R.; Salvatorelli, E.; Menna, P.; Cairo, G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res., 2001, 61, 8422-8428.
17. Beijnen, J.H.; Meenhorst, P.L.; Van Gijn, R.; Fromme, M.; Rosing, H.; Underberg, W.J.M. HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients. J. Pharm. Biomed. Anal., 1991, 9, 995-1002.
18. Sakai-Kato, K.; Saito, E.; Ishikura, K.; Kawanishi. T. Analysis of intracellular doxorubicin and its metabolites by ultra-highperformance liquid chromatography. J. Chromatogr. B, 2010, 878(19), 1466-1470.
19. Wall, R.; McMahon, G.; Crown, J.; Clynes, M.; O'Connor, R. Rapid and sensitive liquid chromatography-tandem mass spec-trometry for the quantitation of epirubicin and identification of metabolites in biological samples. Talanta, 2007, 72, 145-154.
20. Barker, I.K.; Crawford, S.M.; Fell, A.F. Determination of plasma concentrations of epirubicin and its metabolites by highperformance liquid chromatography during a 96-h infusion in cancer chemotherapy. J. Chromatogr. B, 1996, 681, 323-329.
21. Dodde, W.I.; Maring, J.G.; Hendriks, G.; Wachters, F.M.; Groen, H.J.; de Vries, E.G.; Uges, D.R. Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC. Ther. Drug Monit., 2003, 25, 433-440.
22. Lachâtre, F.; Marquet, P.; Ragot, S.; Gaulier, J.M.; Cardot, P.; Du-puy, J.L. Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B, 2000, 738, 281-291.
23. Chang, W.H. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacol. (Berl). 1992, 106, 289-296.
24. Avent, K.M.; DeVoss, J.J.; Gillam, E.M. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem. Res. Toxicol., 2006, 19, 914-920.
25. Aymard, N.; Viala, A.; Stein, I.; Caroli, F. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol de-canoate: Clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma ho-movanillic acid. Progr. Neuro-Psychopharmacol. Biol. Psych., 1995, 19, 1119-1135.
26. Zhou, S.-F.; Zhou, Z.-W.; Huang, M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 2010, 19, 165-188.
27. Hempel, G.; Haberland, S.; Schulze-Westhoff, P.; Möhling, N.; Blaschke, G.; Boos, J. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis. J. Chromatogr. B, 1997, 698, 287-292.
28. Ragnarsson, G.; Bodemar, G. Treatment of irritable bowel syndrome with loperamide oxide. An open study to determine optimal dosage. J. Intern. Med., 2000, 248, 165-166.
29. Sun, WM, Read NW, Verliden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand. J. Gastroen-terol., 1997, 32, 34-38.
30. Kalgutkar, A.S.; Nguyen, H.T. Identification of an N-methyl-4- phenylpyridinium-like metabolite of the antidiarrheal agent lop-eramide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event. Drug Metab. Dispos., 2004, 32, 943-952.
31. Johansen, S.S.; Jensen, J.L. Liquid chromatography-tandem mass spectrometry determination of loperamide and its main metabolite desmethylloperamide in biological specimens and application to forensic cases. J. Chromatogr. B, 2004, 811, 31-36.
32. Anon, M.J. Cancer chemotherapy. Med. Lett. Drugs Ther., 1989, 31, 49-56.
33. Bligh, H.F.; Bartoszek, A.; Robson, C.N.; Hickson, I.D.; Kasper, C.B.; Beggs, J.D.; Wolf, C.R. Activation of mitomycin C by NADPH: cytochrome P-450 reductase. Cancer Res., 1990, 50, 7789-7792.
34. Rump, A.F.; Woschée, U.; Theisohn, M.; Fischbach, R.; Heindel, W.; Lackner, K.; Klaus, W. Pharmacokinetics of intra-arterial mi-tomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres. Eur. J. Clin. Pharmacol., 2002, 58, 459-465.
35. Battino, D.; Estienne, M.; Avanzini, G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Clin. Pharmacokinet., 1995, 29, 341-369.
36. Faigle, J.W.; Menge, G.P. Metabolic characteristics of oxcar-bazepine (Trileptal(R)) and their beneficial implications for enzyme induction and drug interactions. Behav. Neurol. 1990, 3(Suppl. 1), 21-30.
37. Avenoso, A.; Facciolà, G.; Salemi, M.; Spina, E. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J. Chromatogr. B, 2000, 746, 173-181.
38. Rang, H.P.; Dale, M.M.; Ritter, J.M.; Flower, R.J., Eds. Rang and Dale's Pharmacology, 6th ed; Churchill Livingstone Elsevier: Amsterdam, 2007, pp. 427-432.
39. Hirata, H.; Kasama, T.; Sawai, Y.; Fike, R.R. Simultaneous determination of deflazacort metabolites II and III, cortisol, cortisone, prednisolone and prednisone in human serum by reversed-phase high-performance liquid chromatography. J. Chromatogr. B, 1994, 658, 55-61.
40. Garg, V.; Jusko, W.J. Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography. J. Chromatogr. B, 1991, 567, 39-47.
41. Gingell, R.; Bridges, J.W.; Williams, R.T. The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica, 1971, 1, 143-156.
42. Lund, H.I.; Donde, R; Petersen, P.H. A double-blind study comparing sulindac with indomethacin in rheumatoid arthritis. Scand. J. Rheumatol., 1980, 37, 3-6.
43. Etienne, F.; Resnick, L.; Sagher, D.; Brot N.; Weissbach, H. Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Bio-chem. Biophys. Res. Commun., 2003, 312, 1005-1010.
44. Ray, G.F.; Lanman, R.C.; Fu, C.J.; Paranka, N.S.; Pamukcu, R.; Wheeler, S.C. Determination of FGN-1 (an active metabolite of su-lindac) in human plasma, urine, and feces by HPLC. J. Pharm. Biomed. Anal., 1995, 14, 213-220.
45. Product Information: AZULFIDINE(R) Oral Tablets, sulfasalazine. Pharmacia, 2002.
46. Astbury, C. A modified reversed-phase high-performance liquid chromatographic method for the determination of plasma sulphasa-lazine concentrations. J. Pharm. Biomed. Anal., 1988, 6, 103-107.
47. Bystrowska, B.; Nowak, J.; Brandys, J. Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine J. Pharm. Biomed. Anal. 2000, 22, 341-347.
48. Hofmann, U.; Schwab, M.; Treiber, G.; Klotz, U. Sensitive quantification of omeprazole and its metabolites in human plasma by liq-uid chromatography-mass spectrometry. J. Chromatogr. B, 2006, 831, 85-90.
49. Abelö, A.; Andersson, T.B.; Antonsson, M.; Naudot, A.K.; Skån-berg, I.; Weidolf, L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug. Metab. Dispos., 2000, 28, 966-972.
50. th Ed., Lippincott Williams & Wilkins, Philadelphia, 2003.
51. Naser, L.; Rezk, K.C.; Brown, A.; Kashuba, D.M. A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure. J. Chromatogr. B, 2006, 844, 314-321.
52. Warhurst, D.C. Antimalarial drugs. An update. Drugs, 1987, 33, 50-65.
53. Mandell, G.L.; Douglas, R.G.; Bennett, J.E.; Mandell, G.L.; Douglas, R.G,; Bennett, J.E. (Eds): Principles and Practice of Infectious Diseases, 3rd ed. Churchill Livingstone, New York, 1990.
54. Soyinka, J.O.; Onyeji, C.O. Alteration of pharmacokinetics of proguanyl in healthy volunteers following concurrent administration of efavirenz. Eur. J. Pharm. Soc., 2010, 19, 213-218.
55. Kalant, H.; Grant, D.; Mitchell, J.; Principles of Medical Pharmacology, Oxford University Press, Oxford, 2007.
56. http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1. mono-graphs/CPS- %20Monographs/CPS-%20(General%20Monographs-%20A)/ASPIRIN.html
57. Hollenberg, PF; Brody, T.M. Absorbtion, distribution, metabolism and elimination. In, Human Pharmacology Molecular to Clinical, Eds, Brody; Larner;' Minneman, Ch. 4, Mosby, St. Luois, MI, 1998, p. 44.
58. http://www.inchem.org/documents/pims/pharm/aspirin.htm#Sec-tionTitle: 6.4
59. th Ed., McGraw Hill Medical, New York, 2011., p 675.
60. Kmetec, V. Simultaneous determination of acetylsalicylic, salicylic, ascorbic and dehydroascorbic acid by HPLC. J. Pharm. Bio-med. Anal., 1992, 10, 1073-1076.
61. Kees, F.; Jehnich, D.; Grobecker, H. Simultaneous determination of acetylsalicylic acid and salicylic acid in human plasma by highperformance liquid chromatography. J Chromatogr. B, 1996, 677, 172-177.
62. Sjövall, J.; Alván, G.; Westerlund, D. Dose-dependent absorption of amoxycillin and bacampicillin. Clin. Pharmacol. Ther., 1985, 38, 241-250.
63. Sjövall, J.; Westerlund, D.; Alván, G.; Magni, L.; Nord, C.E.; Sörstad, J. Rectal bioavailability of bacampicillin hydrochloride in man as determined by reversed-phase liquid chromatography. Chemotherapy, 1984, 30, 137-147.
64. D'Alonzo, G.E.; Smolensky, M.H.; Feldman, S.; Gnosspelius, Y.; Karlsson, K. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. Chest, 1995, 107, 406-412.
65. Nyberg, L.; Rosenborg, J.; Weibull, E.; Jönsson, S.; Kennedy, B.M.; Nilsson, M. Pharmacokinetics of bambuterol in healthy subjects. Br. J. Clin. Pharmacol., 1998, 45, 471-478.
66. Luo, W.; Zhu, L.; Deng, J.; Liu, A.; Guo, B.; Tan, W.; Dai, R. Simultaneous analysis of bambuterol and its active metabolite ter-butaline enantiomers in rat plasma by chiral liquid chromatogra-phy-tandem mass spectrometry. J. Pharm. Biomed. Anal., 2010, 52, 227-231.
67. Wang, X.-D.; Chan, E.; Chen, X.; Liao, X.X.; Tang, C.; Zhou, Z.W.; Huang, M.; Zhou, S.-F. Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection. J. Pharm. Bio-med. Anal., 2007, 44, 224-230.
68. Stenhoff, H.; Lagerström, P.-O.; Andersen, C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detec tion. J. Chromatogr. B, 1999, 731, 411-417.
69. Hanatani, T.; Fukuda, T.; Ikeda, M.; Imaoka, S.; Hiroi, T.; Funae, Y.; Azuma, J. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J., 2001, 1, 288-292.
70. Kok, R.J.; Grijpstra, F.; Walthuis, R.B.; Moolenaar, F.; de Zeeuw, D.; Meijer, D.K. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J. Pharmacol. Exp. Ther., 1999, 288, 281-285.
71. Kok, R.J.; Visser, J.; Moolenaar, F.; de Zeeuw, D.; Meijer, D.K.F. Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre-or postcolumn fluorescent labeling. J. Chromatogr. B, 1997, 693, 181-189.
72. Neu, H.C. Do we need the third-generation cephalosporins? J. Antimicrob. Chemother., 1984, 14Suppl B, 1-12.
73. Hansen, B.G.; Søgaard P. Population analysis of susceptibility to cefotaxime and desacetyl-cefotaxime in Staphylococcus and En-terobacteriaceae. Acta Pathol. Microbiol. Immunol. Scand. B., 1985, 93, 243-247.
74. Rosseel, M.T.; Vandewoude, K.H. Liquid chromatographic determination of the plasma concentrations of cefotaxime and desacetyl-cefotaxime in plasma of critically ill patients. J. Chromatogr. B., 2004, 811, 159-163.
75. Kakumanu, V.K.; Arora, V.K.; Bansa, A.K. Development and validation of isomer specific RP-HPLC method for quantification of cefpodoxime proxetil. J. Chromatogr. B., 2006, 835, 16-20.
76. www.healthorchid.com/Content/Prod-Health/Spizef.htm
77. http://www.drugs.com/pro/cefuroxime-axetil.html
78. Can, N.Ö; Altiokka, G.; Aboul-Enein, H.Y. Determination of cefu-roxime axetil in tablets and biological fluids using liquid chroma-tography and flow injection analysis. Anal. Chim. Acta, 2006, 576, 246-252.
79. Vasu, S.; Adithan, C.; Shashindran, C.H.; Asad, M.; Koumaravelou, K.; Topno I. Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil. Indian J. Med. Res., 2000, 112, 104-108.
80. Partani, P.; Gurule, S.; Khuroo, A.; Monif, T.; Bhardwaj, S.; Liquid chromatography/electrospray tandem mass spectrometry method for the determination of cefuroxime in human plasma: Application to a pharmacokinetic study. J. Chromatogr. B, 2010, 878, 428-434.
81. Kauffman, R.E.; Thirumoorthi, M.C.; Buckley, J.A.; Aravind, M.K.; Dajani, A.S. Relative bioavailability of intravenous chlo-ramphenicol succinate and oral chloramphenicol palmitate in infants and children. J. Pediatr., 1981, 99, 963-967.
82. th ed., Mc Graw Hill Medical, New York, 2007, p. 752.
83. Csakurda-Harmathy, Zs.; Konkoly-Thege, L. Transformation of chloramphenicol palmitate from therapeutically inactive polymorph A to active polymorph B. Identification and determination of modification A in modification B by DSC. J. Thermal Anal., 1997, 50, 867-871.
84. Gassner, B.; Wuethrich, A. Pharmacokinetic and toxicological aspects of the medication of beef-type calves with an oral formulation of chloramphenicol palmitate. J. Vet. Pharmacol. Ther., 1994, 17, 279-283.
85. Brown, S.A.; Zaya, M.J.; Dieringer, T.M.; Hunter, R.P.; Nappier, J.L.; Hoffman, G.A.; Hornish, R.E.; Yein, F.S. Tissue concentrations of clindamycin after multiple oral doses in normal cats. J. Vet. Pharmacol. Ther., 1990, 13, 270-277.
86. Devlin 3rd, J.L.; Mercer, K.B.; Dea, F.J.; Leopold, I.H. Intraocular penetration of topical clindamycin in rabbits. II. Clindamycin phosphate. Arch. Ophthalmol., 1978, 96, 1650-1652.
87. Cimbollek, M.; Nies, B.; Wenz, R.; Kreuter, J. Antibiotic-impregnated heart valve sewing rings for treatment and prophylaxis of bacterial endocarditis. Antimicrob. Agents Chemother., 1996, 40, 1432-1437.
88. Schreiber, E.C.; Min, B.H.; Zeiger, A.V.; Lang, J.F. Metabolism of diethylpropion-1-C14 hydrochloride by the human. J. Pharmacol. Exp. Ther., 1968, 159, 372-378.
89. Metzler, M.; McLachlan, J.A. Oxidative metabolites of diethylstil-bestrol in the fetal, neonatal and adult mouse. Biochem. Pharmacol., 1978, 27, 1087-1094.
90. Redell, M.A.; Yang, D.C.; Lee, V.H.L. The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits. Int. J. Pharmaceutics, 1983, 17, 299-312.
91. Anderson, J.A.; Davis, W, L.; Wei, C.P. Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the parent compound, epinephrine. Investig. Ophthal. & Visual Sci., 1980, 19, 817-823.
92. West, R.H.; Cebon, L.; Gillies, W.E. Drop attack in glaucoma. The Melbourne experience with topical miotics, adrenergic and neuronal blocking drops. Aust. J. Ophthalmol., 1983, 11, 149-153.
93. Anonymus. Dipivefrin: an adrenaline pro-drug for glaucoma. Drug Ther. Bull., 1985, 23, 27-28.
94. Wall, G.M.; Kenny, J.C.; Fan, T.Y.; Schafer, C.; Ready, M.A.; Baker, J.K.; Ritter, P.; Scott, B.S. Analysis of 3-and 4-monopivaloylepinephrine, degradation products in dipivefrin hy-drochloride drug substance and ophthalmic formulations. J. Pharm. Biomed. Anal., 1992, 10, 465-471.
95. Li, P.; Callery, P.S.; Gan, L.S.; Balani, S.K. Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab. Dispos., 2007, 35, 1023-1031.
96. Lu, S.; Jiang, K.; Qin, F.; Lu, X.; Li, F. Simultaneous quantification of enalapril and enalaprilat in human plasma by highperformance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J. Pharm. Biomed. Anal., 2009, 49, 163-167.
97. Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin. Ther., 2002, 24, 2022-2050.
98. El-Gindy, A.; Emara, S.; K. Mesbah, K.; Hadad, G.M. Spectrophotometric and liquid chromatographic determination of fenofibrate and vinpocetine and their hydrolysis products. Il Far-maco, 2005, 60, 425-438.
99. Lovin, I.; Albu, F.; Tache, F.; David, V.; Medvedovici, A. Solvent and salting effects on sample preparation for the determination of fenofibric acid in human plasma by HPLC-DAD. Microchem. J., 2003, 75, 179-187.
100. Pérez-Elías, M.J.; Morellon, M.L.; Ortega, E.; Hernández-Quero, J.; Rodríguez-Torres, M.; Clotet, B.; Felizarta, F.; Gutiérrez, F.; Pineda, J.A.; Nichols, G.; Lou, Y.; Wire, M.B. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob. Agents Chemother., 2009, 53, 5185-5196.
101. Guaraldi, G.; Cocchi, S.; Codeluppi, M.; Di Benedetto, F.; Bonora, S.; Motta, A.; Luzi, K.; Pecorari, M.; Gennari, W.; Masetti, M.; Ge-runda, G.E.; Esposito, R. Pharmacokinetic interaction between am-prenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant. Proc., 2006, 38, 1138-1140.
102. Cui, S.; Feng, F.; Ma, M.; Liu, H.; Chen, Y. Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma. J. Chromatogr. B., 2007, 854, 143-151.
103. Midha, K.K.; Chakraborty, B.S.; Ganes, D.A. et al: Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J. Clin. Psychopharmacol., 1989, 9, 98-104.
104. Shostak, M.; Perel, J.M.; Stiller, R.L. et al: Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?. J. Clin. Psychopharmacol., 1987, 7, 394-400.
105. Lockridge, O.; Mottershaw-Jackson, N.; Eckerson. H.W.; La Du, B.N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther., 1980, 215, 1-8.
106. Kamendulis, L.M.; Brzezinski, M.R.; Pindel, E.V.; Bosron, W.F.; Dean, R.A. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther., 1996, 279, 713-717.
107. Katagi, M.; Nishikawa, M.; Tatsuno, M.; Miki, A.; Tsuchihashi, H. Column-switching high-performance liquid chromatography-electrospray ionization mass spectrometry for identification of heroin metabolites in human urine. J. Chromatogr. B, 2001, 751, 177-185.
108. van der Bol, J.M.; Mathijssen, R.H.; Creemers, G.J.; Planting, A.S.; Loos, W.J.; Wiemer, E.A.; Friberg, L.E.; Verweij, J.; Sparreboom, A.; de Jong, F.A. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res., 2010, 16, 736-742.
109. Haaz, M.C.; Rivory, L.; Riché, C.; Vernillet, L.; Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 1998, 58, 468-472.
110. Escoriaza, J.; Aldaz, A.; Castellanos, C.; Calvo, E.; Giráldez, J. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. J. Chromatogr. B, 2000, 740, 159-168.
111. Straehl, P.; Galeazzi, R.L.; Solvia, M. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. Clin. Pharmacol. Ther, 1984, 36, 485-492.
112. Straehl, P.; Galeazzi, R.L. Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin. Pharmacol. Ther., 1985, 38, 140-149.
113. Blei, A.T.; Garcia-Tsao, G.; Grossmann, R.J., et al: Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Gastroen-terology, 1987, 93, 576-583.
114. Minamiyama, Y.; Takemura, S.; Imaoka, S.; Yoshihiko, Y.; Okada, S. Cytochrome P450 is Responsible for Nitric Oxide Generation from NO-Aspirin and Other Organic Nitrates. Drug Metab. Pharmacokin., 2007, 22, 15-19.
115. Sun, X.; Li, X.; Cai, S.; Qin, F.; Lu, X.; Li, F. High performance liquid chromatography-electrospray ionization mass spectrometric determination of isosorbide 5-mononitrate in human plasma. J. Chromatogr. B, 2007, 846, 323-328.
116. Mickle, T.; Krishnan, S.; Bishop, B.; Lauderback, C.; Moncrief, J.S.; Oberlender, R.O.; Piccariello, T. inventors, New River Pharmaceuticals, Inc., assignee. Abuse-resistant amphetamine compounds. US patent, 2006, 7, 105, 486.
117. Krishnan, S.; Moncrief, S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab. Dispos., 2007, 35, 180-184.
118. Krishnan. S.; Moncrief S., An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab. Dispos., 2007, 35, 180-184.
119. Boellner, S.W.; Stark, J.G.; Krishnan, S.; Zhang, Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexam-fetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study. Clin. Ther., 2010, 32, 252-264.
120. Duggan, D.E.; Chen, I.W.; Bayne, W.F.; Halpin, R.A.; Duncan, C.A.; Schwartz, M.S.; Stubbs, R.J.; Vickers, S. The physiological disposition of lovastatin. Drug Metab. Dispos., 1989, 17, 166-173.
121. Halpin, R.A.; Ulm, E.H.; Till, A.E.; Kari, P.H.; Vyas, K.P.; Hun-ninghake, D.B.; Duggan, D.E. Biotransformation of lovastatin. Species Differences in In vivo Metabolite Profiles of Mouse, Rat, Dog, and Human. In Drug Metabolism, Am. Soc. Pharmacol. Exp. Ther., Vol. 21, No. 6, 1993.
122. Neuvonen, P.J. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetic. Curr. Opin. Investig. Drugs., 2010, 11, 323-332.
123. Yuan, H.; Wang, F.; Tu, J.; Peng, W.; Li, H. Determination of lovastatin in human plasma by ultra-performance liquid chromatog-raphy-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. J. Pharm. Biomed. Anal., 2008, 46, 808-813.
124. Kysilka, R. Determination of Lovastatin (mevinolin) and mevino-linic acid in fermentation liquids. J. Chromatogr. A, 1993, 630, 415-417.
125. Schoenhard, G.; Oppermann, J.; Kohn, F.E. Metabolism and phar-macokinetic studies of misoprostol. Dig. Dis. Sci. 1985, 30, Suppl.11, 126S-128S.
126. Heikinheimo, O.; Tevilin, M.; Shoupe, D.; Croxatto, H.; Lähteen-mäki P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contracept., 1986, 34, 613-624.
127. Kalász, H; Petroianu, G; Tekes, K.; Klebovich, I.; Ludányi, K.; Gulyás, Z. Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med. Chem. 2007, 3, 101-106.
128. Reden, J. Molsidomine. Blood Vessels, 1990, 27, 282-294.
129. Vanhoutte, P.M.: Concluding remarks. Molsidomine is a donor of EDRF. J. Cardiovasc. Pharmacol., 1989, 14(Suppl. 11), S139-S140.
130. Streel, B; Ceccato, A.; Peerboom, C.; Zimmer, C.; Sibenaler, R.; Maes, P. Determination of molsidomine and its active metabolite in human plasma using liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. A, 1998, 819, 113-123.
131. Han, F.; Liu, G.; Zhang, X.; Li, X.; He, Q.; He, X.; Li, Q.; Wang, S.; Wang, H.; Chen, J. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangi-itis. Am. J. Nephrol., 2011, 33, 185-192.
132. Shum, K.; Askanase, A. Treatment of lupus nephritis. Curr. Rheu-matol. Rep., 2011, 13, 283-290.
133. Bhatia, M.; Militano, O.; Jin, Z.; Figurski, M.; Shaw, L.; Moore, V.; Morris, E.; Tallamy, B.; van deVen, C.; Ayello, J.; Baxter-Lowe, L.; Satwani, P.; George, D.; Bradley, M.B.; Garvin, J.; Cairo, M.S. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tac-rolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol. Blood Marrow Transplant., 2010, 16, 333-343.
134. Zhang, Q.; Tao, Y.; Zhu, Y.; Zhu, D. Bioequivalence and pharma-cokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, two-way crossover study. Clin. Therap., 2010, 32, 171-178.
135. Voros, S.; Sackey, J.Q.; Salles, C.A.; Marbell, E.C.; Grant, F.C.; Nimo, P.K.; Belcher, D.W.; Chew, G.; Adibo, M.E. Sensitivity test on Neisseria meningitidis strains to antimicrobial drugs. Ghana Med. J. 1975, 14, 188-192.
136. www.drugbank.ca/DB00141#pharmacology
137. Chang, H.; Hu, J.; Asami, M.; Kunikane, S. Simultaneous analysis of 16 sulfonamide and trimethoprim antibiotics in environmental waters by liquid chromatography-electrospray tandem mass spec-trometry. J. Chromatogr. A, 2008, 1190, 390-393.
138. Abrams, J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates: choosing the method of administration. Drugs, 1987, 34, 391-403.
139. Noonan, P.K.; Benet, L.Z. Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration. Clin. Pharmacol. Ther., 1987, 42, 273-277.
140. Jensen, K.M.; Dahl, J.B. Plasma concentrations of glyceryl trini-trate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. Arzneimittelforschung, 1994, 44, 951-953.
141. Chen, Z.; Stamler, J. Bioactivation of Nitroglycerin by the Mito-chondrial Aldehyde Dehydrogenase. Trends Cardiovasc. Med. 2006, 16, 259-265
142. Miyayama, T.; Tsou, P.-S.; Fung, S.-M.; Fung, H.-L. Simultaneous determination of nitroglycerin and dinitrate metabolites in metabolism studies using liquid chromatography-mass spectrometry with electrospray ionization. J. Chromatogr. B, 2006, 835, 21-26.
143. http://www.find-health-articles.com/msh-oseltamivir-metabolism.htm
144. Sweeny, D.J.; Lynch, G.; Bifgood, A.M.; Lev, W.; Wang, K.Y.; Cundyy, K.C. Metabolism of the influenza neuraminindase inhibitor prodrug oseltamivir in the rat. Drug Metab. Dispos., 2000, 28, 737-741.
145. Doucette, K.E.; Aoki, F.Y. Oseltamivir: a clinical and pharmacological perspective. Exp.Opin. Pharmacother., 2001, 2, 1671-1683.
146. ®. Legal Medicine, 2008, 10, 83-87.
147. McHardy, G.; Balart, L.A. Jaundice and oxyphenisatin. J. Am. Med. Assoc., 1970, 211, 83-85.
148. Reynolds, T.B.; Lapin, A.C.; Peters, R.L.; Yamahiro, H.S. Puzzling jaundice. J. Am. Med. Assoc., 1970, 211, 86-90.
149. Kok, R.M.; Faber, D.B. Qualitative and quantitative analysis of some synthetic, chemically acting laxatives in urine by gas chroma-tography-mass spectrometry. J. Chromatogr. B., 1981, 222, 389-398.
150. Hoyer, J.; Schulte, K.L.; Lenz, T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin. Pharmacokinet., 1993, 24, 230-254.
151. van den Berg, H.; Resplandy, G.; de Bie, A.T.; Floor, W.; Bertrand, M.; Arts, CJ. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. J. Pharm. Biomed. Anal, 1991, 9, 517-524.
152. Nirogi, R.V.; Kandikere, V.N.; Shukla, M.; Mudigonda, K.; Maurya, S.; Komarneni, P. High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study. Rapid Commun. Mass Spectrom., 2006, 20, 1864-1870.
153. Jurica, J.; Konecny, J.; Zahradníková, L.Z.; Tomandl, J. Simultaneous HPLC determination of tolbutamide, phenacetin and their metabolites as markers of cytochromes 1A2 and 2C6/11 in rat liver perfusate. J. Pharm. Biomed. Anal, 2010, 52, 557-564.
154. http://en.wikipedia.org/wiki/psylocin
155. Laussmann, T.; Meier-Giebing, S. Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis, Forsk) using cation-exchange liquid chromatography. Forensic Sci. Internat., 2010, 195, 160-164.
156. Olson, S.C.; Horvath, A.M.; Michniewicz, B.M.; Sedman, A J.; Colburn, W.A.; Welling, P.G. The clinical pharmacokinetics of quinapril. Angiology, 1989, 40, 351-359.
157. Abbara, Ch.; Aymard, G,; Hinh, S.; Diquet, B. Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B, 2002, 766, 199-207.
158. Becker, R.H.A.; Scholkens, B. Ramipril: review of pharmacology. Am. J. Cardiol., 1987, 59, 3D-1 1D.
159. Ball, S.G.; Robertson, J.I.S. Clinical pharmacology of ramipril. Am. J. Cardiol., 1987, 59, 23D-27D.
160. Zhu, Z.; Vachareau, A.; Neirinck, L. Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma. J. Chromatogr. B, 2002, 779, 297-306.
161. Acocella, G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet., 1978, 3, 108.
162. th ed., McGraw-Hill, New York, 2006, p. 1868.
163. Ye, L.; Stewart, J.T.; Zhang, H. A comparison of disc and cartridge solid-phase extraction for the LC determination of rifampin and 25-desacetylrifampin in human serum. J. Pharm. Biomed. Anal., 1995, 13, 1185-1188.
164. Kaye, S.B.; Workman, P.; Graham, MA., et al: Pharmacokinetics and early clinical studies of selected new drugs. Cancer Surv., 1993, 17, 371-397.
165. van Warmerdam, L.J.C.; Verweij, J.; Schellens, J.H.M., et al: Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days
166. Loos, W.J.; Stoter, G.; Verweij, J.; Schellens, J.H.M. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. J. Chromatogr., B, 1996, 678, 309-315.
167. Duc, L.N.; Brunner, H.R. Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. Am. J. Cardiol., 1992, 70, 27D-34D.
168. Conen, H.; Brunner, H.R. Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am. Heart J., 1993, 125, 1525-1531.
169. Peters, D.C.; Noble, S.; Plosker, G.L. Trandolapril: an update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs, 1998, 56, 871-893.
170. Unger, T.; Ganten, D.; Lang, R.E. Effect of converting enzyme inhibitors of tissue converting enzyme and angiotensin II: therapeutic implications. Am. J. Cardiol., 1987, 59, 18D-22D.
171. Uchino, H.; Kanai, Y.; Kim, D.K.; Wempe, M.F.; Chairoungdua, A.; Morimoto, E.; Anders M.W.; Endou H. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol., 2002, 61, 729-737.
172. Darvas, F.; Marokhazi, S.; Kormos, P.; Kulkarani, G.; Kalasz, H.; Papp, A. MetabolExpert: Its use in metabolism research and in combinatorial chemistry. In Erhardt, P.W. (Ed.) Drug Metabolism, Databases and High-Throughput Testing During Design and Development, IUPAC-Blackwell Science, Oxford, 1999, pp. 237-270.
173. Molnar, L.; Keseru, G.M.; Papp, A.; Gulyas, Zs.; Darvas, F. A neural network based prediction of octanol-water partition coefficients using atomic 5 fragmental descriptors. Bioorg. Med. Chem. Lett., 2004, 14, 851-853.